Exploring Factors behind Patient Nonadherence to Intravitreal Anti-Vascular Endothelial Growth Factor Injections in Macular Diseases
Ophthalmic Research · 2025
DOI: 10.1159/000543352 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ophthalmic Research, 2025. Verfasst von Efrat Naaman und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Rambam Health Care Campus, Haifa, Israel. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Visual Acuity, Ranibizumab, Bevacizumab. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
In recent years, intravitreal injections (IVTs) of vascular endothelial growth factor (VEGF) inhibitors have become the standard of care for several macular disorders. Frequently, the therapeutic course requires numerous injections, posing a burden on patients. Nonadherence to treatment may result in reduced visual outcomes, therefore understanding and addressing the underlying causes is imperative.
Methods
A cross-sectional study of patients who missed their scheduled appointment for anti-VEGF IVT as part of the routine management of their macular disease at a single tertiary center between November 2020 and February 2021. A telephone survey was conducted and patient medical charts were reviewed for ophthalmological data.
Results
A total of 100/556 (18%) patients who failed to attend their scheduled anti-VEGF IVT appointments were documented. Among these subjects, the average age was 66 (SD ± 14) years with a nearly equal gender distribution of 49:51 F:M ratio. Reported no-show reasons included concurrent illness (39%), administrative issues such as missing financial coverage forms or scheduling problems (28%), and lack of motivation (11%). Additionally, 73% of patients who missed appointments expressed a need for accompaniment, and 74% resided outside the hospital city.
Conclusions
Study results highlight modifiable factors contributing to no-shows to anti-VEGF IVT, such as poor transportation access, complicated administrative processes, and difficulty rescheduling missed appointments. Understanding potential obstacles to anti-VEGF IVT therapy, particularly those that are preventable, can enhance adherence and potentially improve the clinical outcome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Rambam Health Care Campus, Haifa, Israel.
- Ruth and Bruce Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel.
- Department of Radiology, Rambam Health Care Campus, Haifa, Israel.
- Department of Ophthalmology, Rabin Medical Center, Petah Tikva, Israel.
Zitieren
APA
Naaman, E., Yanir-Prat, N., Shair-Nakhleh, D., Bar, N., Miller, B., Fishman, A., & Zayit-Soudry, S. (2025). Exploring Factors behind Patient Nonadherence to Intravitreal Anti-Vascular Endothelial Growth Factor Injections in Macular Diseases. Ophthalmic Research. https://doi.org/10.1159/000543352
Vancouver
Naaman E, Yanir-Prat N, Shair-Nakhleh D, Bar N, Miller B, Fishman A, et al. Exploring Factors behind Patient Nonadherence to Intravitreal Anti-Vascular Endothelial Growth Factor Injections in Macular Diseases. Ophthalmic Research. 2025. doi:10.1159/000543352
BibTeX
@article{Naaman2025,
author = {Naaman, Efrat and Yanir-Prat, Noa and Shair-Nakhleh, Diana and Bar, Nitai and Miller, Beata and Fishman, Anna and Zayit-Soudry, Shiri},
title = {Exploring Factors behind Patient Nonadherence to Intravitreal Anti-Vascular Endothelial Growth Factor Injections in Macular Diseases},
journal = {Ophthalmic Research},
year = {2025},
doi = {10.1159/000543352}
}
EUVIMED